In another study, Kompier and colleagues [72] confirmed the correlations between a low risk of progression and better disease-specific survival in the primary mutant FGFR3 tumor and worse prognosis in the group of patients with an overexpression of p53. The gene discussed is TP53; the disease is neoplasm.